Shots:
- J&J has reported P-III (ICONIC-TOTAL) trial data assessing icotrokinra (QD, PO; n=208) vs PBO (n=103) in 311 PsO pts (≥12yrs.) with ≥1% body surface area & at least mod. plaque PsO at high-impact sites
- At Wk. 16, trial met its 1EP, with 57% vs 6% achieving IGA 0/1 & ≥2-grade improvement while in scalp PsO, 66% vs 11% pts reached ss-IGA 0/1. In genital PsO, 77% vs 21% achieved sPGA-G 0/1, plus 42% vs 26% pts with hand/foot PsO reached hf-PGA 0/1; data was shared at SID 2025
- Icotrokinra (JNJ-2113) is being assessed in ICONIC Program: ICONIC LEAD (vs PBO) for mod. to sev. plaque PsO, ICONIC-ADVANCE 1 & 2 (vs PBO & Sotyktu) & ICONIC-ASCEND (vs PBO & Stelara) for mod. to sev. PsO, plus ICONIC-PsA 1 & 2 (vs PBO) for active PsA
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson’s Tremfya Receives the EC’s Approval for Active Ulcerative Colitis (UC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
